Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
, 96 (32), e7697

Berberine Containing Quadruple Therapy for Initial Helicobacter Pylori Eradication: An Open-Label Randomized Phase IV Trial

Affiliations
Clinical Trial

Berberine Containing Quadruple Therapy for Initial Helicobacter Pylori Eradication: An Open-Label Randomized Phase IV Trial

Di Zhang et al. Medicine (Baltimore).

Abstract

Background: Due to increasing antimicrobial resistance, a bismuth-based quadruple regimen has been recommended as an alternative first-line therapy for Helicobacter pylori (H pylori) eradication. However, different results are varied greatly and the availability of bismuth was limited in some countries. We assessed the efficacy and safety of 14-day berberine-containing quadruple therapy as an alternative regimen for H pylori eradication.

Methods: In a randomized, open-label, non-inferiority, phase IV trial between November 25, 2014, and October 15, 2015, 612 treatment-naive patients were randomly assigned to 14-day berberine-containing (n = 308) or 14-day bismuth-containing (n = 304) quadruple therapy. The primary outcomes were eradication rates determined by the C urea breath test (C-UBT) 28 days after the end of treatment. The secondary outcomes were adverse events and compliance.

Results: The baseline demographic data including age, gender, body mass index (BMI), general condition and severity score were not statistically different in both groups. The eradication rates in bismuth and berberine groups were 86.4% (266/308) and 90.1% (274/304) in intention-to-treat (ITT) analysis (P = .149), and 89.6% (266/297) and 91.3% (273/299) in per-protocol (PP) analysis (P = .470), respectively. No statistically significant difference was found in the overall incidence of adverse events between both groups (35.7% vs 28.6%, P = .060).

Conclusions: Both regimens achieved the recommended efficacy for H pylori eradication. The berberine-containing quadruple regimen was not inferior to bismuth-containing quadruple regimen and can be recommended as an alternative regimen for H pylori eradication in the local region.

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Participant flow.

Similar articles

See all similar articles

Cited by 5 articles

References

    1. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002;347:1175–86. - PubMed
    1. Malfertheiner P, Chan FK, McColl KE. Peptic ulcer disease. Lancet 2009;374:1449–61. - PubMed
    1. Zhang WD, Hu FL, Xiao SD, et al. Prevalence of Helicobacter pylori infection in China. Xiandai Xiaohua Ji Jieru Zhenliao 2010;15:265–70. in Chinese.
    1. Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015;64:1353–67. - PMC - PubMed
    1. McColl KE. Clinical practice. Helicobacter pylori infection. N Engl J Med 2010;362:1597–604. - PubMed

Publication types

MeSH terms

Feedback